NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

OTC Markets · Biotechnology · USD

Anebulo Pharmaceuticals, Inc. (ANEB) Stock Analysis

Anebulo Pharmaceuticals, Inc. (ANEB) is a Biotechnology stock listed on OTC Markets and quoted in US Dollar.

Last Updated: October 20, 2026

ANEB

$0.30

+$0.29 (+29,400.00%)

Oct 20, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ANEB with… →

ANEB Key Statistics

As of Oct 20, 2026
Trading
Open
$0.30
Previous Close
$0.001
52-Week Range
0.001–2.77
Volume
100.00
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.89
Valuation
Market Cap
$12.03M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.19
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$8.48M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
40.78M
1-Year Return
−89.03%
Dividend and dates
Avg Volume
210.00

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 20, 2026, ANEB closed at $0.30, −89.03% over 1 year.

Anebulo Pharmaceuticals, Inc. (ANEB) has a market capitalization of $12.03M.

In fiscal 2025, ANEB reported revenue of $0.00.

ANEB Stock Return by Calendar Year

Anebulo Pharmaceuticals, Inc. (ANEB) return since May 2021: what $10,000 became

1 year
$10,000 $1,097
−89.03%
5 years
$10,000 $422
−95.78%
Since May 2021
$10,000 $415
−95.85%

If you had invested $10,000 in Anebulo Pharmaceuticals, Inc. (ANEB) at the close on May 7, 2021, the earliest close on record here, it would have been worth $415 at the close on October 20, 2026: −95.85% in total, −44.19% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−70.79%
2025−39.88%
2024−30.58%
2023−0.17%
2022−60.59%
2021 (partial year)−13.38%

As of October 20, 2026.

ANEB Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$8.48M—
2024$0.00−$8.20M—
2023$0.00−$11.73M—
2022$0.00−$6.83M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$8.36M−$8.48M—
2024$0.00—−$8.31M−$8.20M—
2023$0.00—−$11.78M−$11.73M—
2022$0.00—−$6.83M−$6.83M—

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

Analysis

Data-derived

Company Overview

The market values Anebulo Pharmaceuticals, Inc. (ANEB) at $12.03M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 2 employees.

The 52-week range on file runs from $0.001 to $2.77. ANEB last closed at $0.30 on October 20, 2026. That is +$0.29 (+29,400.00%) against the previous close. The latest close sits 29,400% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $8.48M. Earnings per share on a trailing basis come to −0.19.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at −1.89. Daily returns over the trailing 5 years annualize to a volatility of 19,779.78%. Over the trailing twelve months the total return is −89.03%. Measured over 5 years, that is −46.90% a year compounded.

Growth & Income

No dividend is on file for ANEB.

So far in 2026 the total return is −70.79%. The strongest complete calendar year on file is 2023 at −0.17%; the weakest is 2022 at −60.59%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Anebulo Pharmaceuticals, Inc. (ANEB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Anebulo Pharmaceuticals, Inc. ANEB $12.03M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Anebulo Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 20, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

Visit website →